NCT06965114 2026-03-18
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT05465174 2026-03-09
PNOC029
University of California, San Francisco
Phase 2 Recruiting
NCT05566795 2026-03-02
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
Day One Biopharmaceuticals, Inc.
Phase 3 Recruiting
NCT07441707 2026-03-02
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Ipsen
Phase 1 Not yet recruiting
NCT03429803 2026-02-19
DAY101 In Gliomas and Other Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07206849 2025-10-29
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
Nationwide Children's Hospital
Phase 2 Not yet recruiting
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT07121829 2025-08-14
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Terminated
NCT04775485 2025-04-10
FIREFLY-1
Day One Biopharmaceuticals, Inc.
Phase 2 Recruiting
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT02723006 2024-03-05
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Takeda
Phase 1 Terminated
NCT01425008 2020-08-10
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
Takeda
Phase 1 Completed
NCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed